Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.54 |
| ▸ | CCR4 | P51679 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 4/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KIF5B | P33176 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932224 | 0.90 | BRAF (0.65) | BRAFCCR4AURKARPS6KB1MAPK1 | |
| SCHEMBL9932683 | 0.88 | BRAF (0.56) | BRAFCCR4MAPK1EGFRFGFR1 | |
| SCHEMBL9932383 | 0.86 | BRAF (0.59) | BRAFCCR4AURKARPS6KB1MAPK1 | |
| SCHEMBL9932715 | 0.83 | BRAF (0.59) | BRAFCCR4AURKARPS6KB1MAPK1 | |
| SCHEMBL9967960 | 0.82 | BRAF (0.75) | BRAFCCR4 | |
| SCHEMBL9933461 | 0.81 | BRAF (0.59) | BRAFCCR4AURKARPS6KB1MAPK1 | |
| SCHEMBL9967969 | 0.80 | BRAF (0.85) | BRAFCCR4 | |
| SCHEMBL9932385 | 0.78 | BRAF (0.60) | BRAFCCR4MAPK1RETKIF5B | |
| SCHEMBL9932228 | 0.78 | BRAF (0.67) | BRAFCCR4MAPK1KDR | |
| SCHEMBL9932530 | 0.78 | LMNA (0.37) | BRAFAURKAEGFRFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885CCR4 3948/4885AURKA 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.